Clinical Trial Search

Primary: Change From Baseline in Schiff Sensitivity Score After 8 Weeks of Treatment — 2.22; 2.23; 2.18; 1.69 Score on Scale — p=0.0476

Primary: Area Under the Curve of Alfentanil Concentration vs. Time Extrapolated to Infinity — 58; 57; 55; 73 (hr*ng/ml/mg) — p=<.05

Primary: Non Administration of Prescribed VTE Prophylaxis Medication Doses — 10.8; 14.5; 9.2; 13.5 percentage of nonadministration — p=0.05

Primary: Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 89.6 percentage of participants

Primary: Mesure of the Train-of-four (TOF) — 3.8; 4.5; 11.5; 19 minute

Primary: Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision. — 8.3; 8.5 ETDRS Letters

Primary: Recovery of Bowel Function — 43.2; 34.0 Hours

Primary: Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population. — 22 Participants

Primary: Visual Analogue Scale (VAS) 0-10 Pain Rating — 4.3; 7.2 units on a scale

Primary: Percentage Change in LDL-C From Baseline to Day 180 — 2.1; -27.9; -38.4; -41.9 Percent change — p=<0.0001

Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 2.75; 1.38; 1.38; 4.75 cocaine choices

Primary: Overall Survival (OS) — 8.51; 7.29 Months — p=0.0199

Primary: Changes in [11C]-(+)-PHNO Binding (Measured as Binding Potential) in Dorsal Caudate (DC) — 2.1 binding potential

Primary: Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization — 10 Participants

Primary: Intraoperative Opioid Administration — 25; 5.6; 8.6 morphine equivalents mg — p=0.0001